Wellington Management Group LLP Sells 3,451 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Wellington Management Group LLP cut its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133,263 shares of the company’s stock after selling 3,451 shares during the period. Wellington Management Group LLP owned 0.30% of Y-mAbs Therapeutics worth $1,043,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in YMAB. KLP Kapitalforvaltning AS bought a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $46,000. SG Americas Securities LLC increased its position in Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after buying an additional 4,163 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock worth $174,000 after buying an additional 1,903 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Y-mAbs Therapeutics by 6,911.6% in the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock valued at $212,000 after acquiring an additional 26,748 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after acquiring an additional 2,854 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Up 11.0 %

Shares of Y-mAbs Therapeutics stock opened at $4.83 on Monday. The firm’s 50 day moving average is $5.18 and its 200 day moving average is $8.75. The firm has a market capitalization of $218.40 million, a PE ratio of -8.94 and a beta of 0.71. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.86 and a 1 year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. During the same period in the previous year, the firm posted ($0.02) EPS. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 22.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on YMAB. Bank of America dropped their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. HC Wainwright cut their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Finally, Truist Financial dropped their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.